Bromantane

Overview

Bromantane is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. Sold there as the prescription drug Ladasten, it has no FDA or EMA approval and no blinded, placebo-controlled human trials; it is WADA-prohibited in sport and circulates on the gray market as a research chemical.

Mechanism of Action

Bromantane's mechanism is not fully established. In rats and in vitro it regulates tyrosine hydroxylase (TH) mRNA and protein and increases TH gene transcription via cytosine demethylation of CpG islands in the TH promoter — an epigenetic route to enhanced dopamine biosynthesis — alongside anxiolytic, immunomodulatory, and antioxidant/membrane-protective effects. All mechanistic data are animal or in-vitro; there are no human mechanistic studies.

Research Summary

Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.

Reported Side Effects

• Adverse effects reported in ~3% of patients in the single Russian open-label trial — no controlled (blinded, placebo) human safety data exist
• Human safety outside the Russian asthenia indication is uncharacterized
• Prohibited in sport — WADA S6 stimulant, with a historical Olympic doping scandal (Atlanta 1996)
• Gray-market products are unregulated with no independent identity or purity verification

Compare Bromantane with Others

Research References

• Voznesenskaia TG, Fokina NM, Iakhno NN. Ladasten in the treatment of asthenic disorders: a multicenter open-label study. 2010. PMID 21322821.
• Mikhaylova M, et al. Bromantane (ladasten) regulation of tyrosine hydroxylase and dopamine. Neuropharmacology. 2007. PMID 17854844.
• Sokolov AV, et al. The pharmacological and clinical profile of ladasten (bromantane) — review. 2013. PMC3762282.
• Docherty JR. The pharmacology of stimulants prohibited in sport. Br J Pharmacol. 2008. PMC2439527.

Frequently asked questions

Has Bromantane been independently lab-tested?

Disclosed Labs has collected 4 Certificates of Analysis (COA) for Bromantane from 3 independent testing labs. 1 vendor has submitted material for testing. Products average 99.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/bromantane/testing.

What is the average purity of Bromantane on the market?

Based on 4 COAs analyzed by Disclosed Labs, Bromantane products average 99.9% (±0.1%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/bromantane/coas.

How does Bromantane work?

Bromantane's mechanism is not fully established. In rats and in vitro it regulates tyrosine hydroxylase (TH) mRNA and protein and increases TH gene transcription via cytosine demethylation of CpG islands in the TH promoter — an epigenetic route to enhanced dopamine biosynthesis — alongside anxiolytic, immunomodulatory, and antioxidant/membrane-protective effects. All mechanistic data are animal or in-vitro; there are no human mechanistic studies.

What does the research say about Bromantane?

Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.